Diabetogenic effects of salmon calcitonin are attributable to amylin-like activity

被引:28
作者
Young, AA
Wang, MW
Gedulin, B
Rink, TJ
Pittner, R
Beaumont, K
机构
[1] Amylin Pharmaceuticals, San Diego, CA
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 1995年 / 44卷 / 12期
关键词
D O I
10.1016/0026-0495(95)90079-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
During the development of synthetic calcitonins for therapeutic use in hone disease, a ''diabetogenic'' (hyperglycemic) effect was observed, particularly with salmon calcitonin. The effect was attributed by some to inhibition of insulin secretion. We have recently reported high-affinity (28 pmol/L) amylin binding sites in certain areas of rat brain, and found that these sites also bind salmon but not rat calcitonin with comparable high affinity. Rat amylin end salmon calcitonin have been determined to have significant structural homology. In vitro and in vivo studies indicate that rat amylin can exert calcitonin-like effects on osteoclasts and on plasma calcium. Here we report that salmon calcitonin mimics the actions of rat amylin on skeletal muscle glycogen metabolism in vitro; it stimulates glycogenolysis and inhibits incorporation of radiolabeled glucose into glycogen (50% effective concentration [EC(50)], 0.4 +/- 0.11 nmol/L log and 8.4 +/- 0.05 nmol/L log, respectively). In anesthetized rats, salmon calcitonin, like rat amylin, rapidly increases plasma lactate concentration, followed by a slower increase in glucose concentration. Like amylin, salmon calcitonin also inhibits the insulin response to 2 mmol infused glucose (insulin increments suppressed by 52% and 57% at 10 minutes for salmon calcitonin and amylin). Other shared actions, such as suppression of appetite, stimulation of renin secretion, inhibition of gastric acid secretion, and inhibition of gastric emptying, further affirm our proposal that the exogenous peptide, salmon calcitonin, is a mimic of endogenous amylin in the rat. Copyright (C) 1995 by W.B. Saunders Company
引用
收藏
页码:1581 / 1589
页数:9
相关论文
共 58 条
  • [1] AZRIA M, 1989, CALCITONINS PHYSL PH, P133
  • [2] BEAUMONT K, 1993, MOL PHARMACOL, V44, P493
  • [3] BEAUMONT K, 1993, DIABETES, V42, pA215
  • [4] BRAIN SD, 1990, AM J PATHOL, V136, P487
  • [5] BROWN K, 1994, DIABETES, V43, pA172
  • [6] ANOREXIA FOLLOWING THE INTRAHYPOTHALAMIC ADMINISTRATION OF AMYLIN
    CHANCE, WT
    BALASUBRAMANIAM, A
    ZHANG, FS
    WIMALAWANSA, SJ
    FISCHER, JE
    [J]. BRAIN RESEARCH, 1991, 539 (02) : 352 - 354
  • [7] EFFECTS OF SALMON-CALCITONIN ON PLASMA-RENIN ACTIVITY AND SYSTOLIC BLOOD-PRESSURE IN THE RAT
    CLEMENTI, G
    RAPISARDA, E
    FIORE, CE
    PRATO, A
    AMICOROXAS, M
    MILLIA, C
    BERNARDINI, R
    MAUGERI, S
    SCAPAGNINI, U
    [J]. NEUROSCIENCE LETTERS, 1986, 66 (03) : 351 - 355
  • [8] PURIFICATION AND CHARACTERIZATION OF A PEPTIDE FROM AMYLOID-RICH PANCREASES OF TYPE-2 DIABETIC-PATIENTS
    COOPER, GJS
    WILLIS, AC
    CLARK, A
    TURNER, RC
    SIM, RB
    REID, KBM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (23) : 8628 - 8632
  • [9] INVIVO AND INVITRO EFFECTS OF AMYLIN AND AMYLIN-AMIDE ON CALCIUM-METABOLISM IN THE RAT AND RABBIT
    DATTA, HK
    ZAIDI, M
    WIMALAWANSA, SJ
    GHATEI, MA
    BEACHAM, JL
    BLOOM, SR
    MACINTYRE, I
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 162 (02) : 876 - 881
  • [10] AMYLIN INHIBITS GLUCOSE-INDUCED INSULIN-SECRETION IN A DOSE-DEPENDENT MANNER - STUDY IN THE PERFUSED RAT PANCREAS
    DEGANO, P
    SILVESTRE, RA
    SALAS, M
    PEIRO, E
    MARCO, J
    [J]. REGULATORY PEPTIDES, 1993, 43 (1-2) : 91 - 96